{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:48:59Z","timestamp":1791193739931,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2007,5,18]],"date-time":"2007-05-18T00:00:00Z","timestamp":1179446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients \u226570 years of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Sixty\u2010four previously untreated patients with CLL and serum creatinine &lt;1.5 times the upper limit of normal who met National Cancer Institute (NCI) 96\u2010WG criteria for treatment received pentostatin (2 mg\/m<jats:sup>2<\/jats:sup>), cyclophosphamide (600 mg\/m<jats:sup>2<\/jats:sup>), and rituximab (375 mg\/m<jats:sup>2<\/jats:sup>). The authors measured performance status at study entry and used age, weight, and baseline creatinine to calculate creatinine clearance (CrCl).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Eighteen of 64 (28%) patients were ages \u226570 years. Although individuals ages \u226570 years were more likely to have delayed treatment cycles (28% vs 7%; <jats:italic>P<\/jats:italic> = .03), there were no significant differences in the number of cycles administered, need for dose reductions, or grade 3\u20134 hematologic, infectious, or other toxicities. No significant differences in overall response rate, complete response rate, or progression\u2010free survival were observed by age. Twenty\u2010five (39%) patients had a CrCl &lt; 70 mL\/min (range, 34\u201367). Although individuals with CrCl &lt; 70 were more likely to require dose reduction (24% vs 5%; <jats:italic>P<\/jats:italic> = .05), there were no significant differences in the number of cycles administered or grade 3\u20134 hematologic, infectious, or other toxicities. No significant difference in overall response rate, complete response rate, or progression\u2010free survival were observed between patients with CrCl \u2265 70 mL\/min and those with CrCl &lt; 70 mL\/min.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>In this clinical trial, the PCR regimen was well tolerated by older patients and individuals with CrCl \u2264 70. The efficacy of PCR was not significantly affected by age or renal function. These findings suggest PCR may be a good therapeutic option for older patients and those with modestly decreased renal function. Cancer 2007; 109:2291\u20138. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22662","type":"journal-article","created":{"date-parts":[[2007,5,27]],"date-time":"2007-05-27T03:48:27Z","timestamp":1180237707000},"page":"2291-2298","source":"Crossref","is-referenced-by-count":121,"title":["Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"109","author":[{"given":"Tait D.","family":"Shanafelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive S.","family":"Zent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,5,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62215-0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2004.00489.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400679"},{"key":"e_1_2_5_5_2","first-page":"8","article-title":"What is changing in the natural history of chronic lymphocytic leukemia?","volume":"86","author":"Molica S","year":"2001","journal-title":"Haematologica."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2684::AID-CNCR13>3.0.CO;2-V"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0972"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03959.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6037"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"e_1_2_5_15_2","first-page":"S86","article-title":"Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients","volume":"46","author":"Ferrajoli A","year":"2005","journal-title":"Leuk Lymphoma."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1196"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.433"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.17.1416"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.217"},{"key":"e_1_2_5_20_2","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"Grever MR","year":"1988","journal-title":"Nouv Rev Fr Hematol."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.19"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.44"},{"key":"e_1_2_5_23_2","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first\u2010line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial","volume":"96","author":"Robak T","year":"2000","journal-title":"Blood."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2319"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4828"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3836"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.100"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033274"},{"issue":"2","key":"e_1_2_5_32_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Amer J Kidney Diseases."},{"key":"e_1_2_5_33_2","first-page":"1988","volume-title":"common toxicity criteria","author":"National Cancer Institute","year":"1988"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.285"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0749-0690(18)30167-8","article-title":"Chronic lymphocytic leukemia in the elderly population","volume":"13","author":"Rai KR","year":"1997","journal-title":"Clin Geriatr Med."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200016010-00002"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199909083391"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000110991"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22662","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:00:54Z","timestamp":1760277654000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,18]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1002\/cncr.22662"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22662","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,18]]}}}